SUTRO BIOPHARMA, INC. (STRO) Form 8-K — May 14, 2026
Sutro Biopharma reported Q1 2026 revenue of $14.5 million and a net loss of $38.5 million, significantly improved from a $76.0 million net loss in the prior year quarter due to the completion of restructuring activities. Operating expenses dropped to $44.2 million from $85.9 million year-over-year, reflecting disciplined cost management. The company strengthened its balance sheet with a $110 million underwritten equity offering at $13.98 per share, bringing total cash and marketable securities to $202.6 million. This capital raise extends Sutro’s cash runway into at least the second quarter of 2028, providing ample funding for clinical development.
Key figures
- Revenue
- 14523000
- Total Debt
- 229105000
- Total Assets
- 241988000
- Cash Position
- 202558000
- Cash Runway
- Q2 2028
- Operating Expenses
- 44179000
- Operating Expenses Yo Y
- 85913000
- Milestone Payment Astellas
- 10000000
- Gross Proceeds Capital Raise
- 110000000
- Offering Price Capital Raise
- 13.98
- Shares Offered Capital Raise
- 7868383
Price after filing
Close on the filing date to close N calendar days later (from $38.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.